Role of lipid peroxide in the neurodegenerative disorders

Sub-Cellular Biochemistry

Volumn 77, Issue , 2014, Pages 127-136

  Maruyama, Wakako ^a   Shaomoto Nagai, Masayo ^a   Kato, Yoji ^b   Hisaka, Shinsuke ^c   Osawa, Toshihiko ^d   Naoi, Makoto ^d  

^a National Center for Geriatrics and Gerontology   (Japan)

^b UNIVERSITY OF HYOGO   (Japan)

^c MEIJO UNIVERSITY   (Japan)

^d AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Brain ageing; Lipid peroxidation; Oxidatively modified protein; Parkinson disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; LIPID PEROXIDE; OMEGA 3 FATTY ACID; UNSATURATED FATTY ACID;

BRAIN; DEGENERATIVE DISEASE; HUMAN; METABOLISM; NERVE CELL; OXIDATIVE STRESS; PATHOLOGY;

ALPHA-SYNUCLEIN; BRAIN; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; HUMANS; LIPID PEROXIDES; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATIVE STRESS;

EID: 84899781943     PISSN: 03060225     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-007-7920-4_11     Document Type: Article

References (33)

1. Baur JA (2010) Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev 131:261-269
2. Bazan NG, Molina MF, Gordon WC (2011) Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Annu Rev Nutr 31:321-351
3. Berman DR, Mozurkewich E, Liu Y, Barks J (2009) Docosahexaenoic acid pretreatment confers neuroprotection in a rat model of perinatal cerebral hypoxia-ischemia. Am J Obstet Gynecol 200(305):e301-e306
4. Carlsson A (1978) Age-dependent changes in central dopaminergic and other monoaminergic systems. Adv Exp Med Biol 113:1-13
5. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MB (2000) Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67:577-585
6. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816-830
7. Eady TN, Belayev L, Khoutorova L, Atkins KD, Zhang C, Bazan NG (2012) Docosahexaenoic acid signaling modulates cell survival in experimental ischemic stroke penumbra and initiates long-term repair in young and aged rats. PLoS One 7:e46151
8. Exner N, Lutz AK, Haass C, Winklhofer KF (2012) Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J 31:3038-3062
9. Fujita Y, Ito M, Nozawa Y, Yoneda M, Oshida Y, Tanaka M (2007) CHOP (C/EBP homologous protein) and ASNS (asparagine synthetase) induction in cybrid cells harboring MELAS and NARP mitochondrial DNA mutations. Mitochondrion 7:80-88
10. Gleissman H, Yang R, Martinod K, Lindskog M, Serhan CN, Johnsen JI, Kogner P (2010) Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J 24:906-915
11. Glozman S, Green P, Yavin E (1998) Intraamniotic ethyl docosahexaenoate administration protects fetal rat brain from ischemic stress. J Neurochem 70:2484-2491
12. Hisaka S, Kato Y, Kitamoto N, Yoshida A, Kubushiro Y, Naito M, Osawa T (2009) Chemical and immunochemical identification of propanoyllysine derived from oxidized n-3 polyunsaturated fatty acid. Free Radic Biol Med 46:1463-1471
13. Kato Y, Osawa T (2010) Detection of lipid-lysine amide-type adduct as a marker of PUFA oxidation and its applications. Arch Biochem Biophys 501:182-187
14. Kawai Y, Fujii H, Okada M, Tsuchie Y, Uchida K, Osawa T (2006) Formation of Nepsilon- (succinyl)lysine in vivo: a novel marker for docosahexaenoic acid-derived protein modification. J Lipid Res 47:1386-1398
15. Kitani K, Yokozawa T, Osawa T (2004) Interventions in aging and age-associated pathologies by means of nutritional approaches. Ann N Y Acad Sci 1019:424-426
16. Knoll J (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Dev 46:237-262
17. Maruyama W, Naoi M (2013) “70th Birthday Professor Riederer” Induction of glial cell linederived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy? J Neural Transm 120:83-89
18. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M (2002) Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24:675-682
19. Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Yodim M, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 44:393-400
20. Mattson MP, Magnus T (2006) Ageing and neuronal vulnerability. Nat Rev Neurosci 7:278-294
21. Morgan-Hughes JA, Hayes DJ, Clark JB, Landon DN, Swash M, Stark RJ, Rudge P (1982) Mitochondrial encephalomyopathies: biochemical studies in two cases revealing defects in the respiratory chain. Brain 105(Pt 3):553-582
22. Naoi M, Maruyama W (2009) Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease. Expert Rev Neurother 9:1233-1250
23. Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharm Des 16:2799-2817
24. Orimo S, Oka T, Miura H, Tsuchiya K, Mori F, Wakabayashi K, Nagao T, Yokochi M (2002) Sympathetic cardiac denervation in Parkinson’s disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 73:776-777
25. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL (2007) Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem 282:5862-5870
26. Rubinsztein DC, Marino G, Kroemer G (2011) Autophagy and aging. Cell 146:682-695
27. Shamoto-Nagai M, Maruyama W, Hashizume Y, Yoshida M, Osawa T, Riederer P, Naoi M (2007) In Parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural Transm 114:1559-1567
28. Shamoto-Nagai M, Hisaka S, Akao Y, Osawa T, Naoi M, Maruyama W (in preparation) A membrane-component, docosahexaenoic acid induces neuronal cell death with accumulation of abnormal-synuclein modified by lipid-peroxides: its relevance to the pathogenesis of Parkinson disease
29. Wurtman RJ, Cansev M, Sakamoto T, Ulus I (2010) Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr Rev 68(Suppl 2):S88-S101
30. Xiang L, Nakamura Y, Lim YM, Yamasaki Y, Kurokawa-Nose Y, Maruyama W, Osawa T, Matsuura A, Motoyama N, Tsuda L (2011) Tetrahydrocurcumin extends life span and inhibits the oxidative stress response by regulating the FOXO forkhead transcription factor. Aging (Albany NY) 3:1098-1109
31. Yakunin E, Loeb V, Kisos H, Biala Y, Yehuda S, Yaari Y, Selkoe DJ, Sharon R (2012) Alphasynuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson’s disease. Brain Pathol 22:280-294
32. Yavin E, Glozman S, Green P (2001) Docosahexaenoic acid accumulation in the prenatal brain: prooxidant and antioxidant features. J Mol Neurosci 16:229-235; discussion 279-284
33. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93:2696-2701